Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman Sells 40,000 Shares of Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the completion of the transaction, the director now owns 601,233 shares of the company’s stock, valued at $27,067,509.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Hoffman also recently made the following trade(s):

• On Monday, September 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $45.83, for a total value of $1,833,200.00.

Inari Medical Stock Up 1.7 %

Shares of NASDAQ NARI opened at $44.23 on Friday. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $67.13. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -107.88 and a beta of 1.00. The company’s fifty day moving average is $44.11 and its 200-day moving average is $45.83.

Inari Medical (NASDAQ:NARI) last posted its earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.25). Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%. The business had revenue of $145.82 million for the quarter, compared to the consensus estimate of $143.96 million. On average, research analysts anticipate that Inari Medical, Inc. will post -0.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NARI shares. Truist Financial decreased their price target on Inari Medical from $55.00 to $46.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Wells Fargo & Company cut their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Leerink Partners initiated coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 price target for the company. Robert W. Baird cut their price objective on shares of Inari Medical from $65.00 to $63.00 and set an “outperform” rating on the stock in a report on Wednesday, July 31st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a research note on Wednesday, October 9th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Inari Medical has a consensus rating of “Hold” and an average price target of $57.44.

Hedge Funds Weigh In On Inari Medical

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Inari Medical by 6.9% in the fourth quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock valued at $327,086,000 after buying an additional 325,586 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Inari Medical by 462.4% in the 1st quarter. State of Alaska Department of Revenue now owns 31,095 shares of the company’s stock worth $1,491,000 after purchasing an additional 25,566 shares during the period. Maryland State Retirement & Pension System bought a new position in Inari Medical during the 1st quarter worth about $886,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Inari Medical in the 1st quarter valued at about $30,000. Finally, Texas Permanent School Fund Corp raised its stake in shares of Inari Medical by 1.5% in the 1st quarter. Texas Permanent School Fund Corp now owns 44,858 shares of the company’s stock valued at $2,152,000 after purchasing an additional 664 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.